Latest Governance And Leadership News

Macquarie Technology Group Limited reported solid FY25 results with continued EBITDA growth and strong cash conversion, underpinned by strategic investments in data centre capacity and AI capabilities.

Platinum Asset Management reported a sharp 86% drop in profit for FY25, driven by a 39% decline in funds under management amid sustained outflows and investment challenges. The company announced a transformative merger with L1 Capital, aiming to create a $16.5 billion asset manager.

H&G High Conviction Limited reported a $2.9 million net loss for FY2025 amid challenging market conditions and completed a major asset sale to Hancock & Gore Limited, marking a pivotal shift in its business model.

Associate Global Partners Limited reported a 14% revenue increase to $7.085 million for FY2025, driven by strong fund growth and improved performance fees. The net loss after tax narrowed significantly to $171,000, reflecting operational progress despite no dividend declaration.

WiseTech Global reported a robust FY25 with 14% revenue growth and a 17% rise in net profit, underpinned by a transformative $2.1 billion acquisition of e2open and strategic leadership changes.

Woolworths Group posted a modest 1.7% revenue increase to $69.1 billion for the 52 weeks ending June 2025, while earnings before interest and tax (EBIT) fell 12.6%, weighed down by challenges in its Australian Food and BIG W segments.

Ironbark Capital Limited reported a 17.6% increase in net profit for FY2025, driven by higher investment income and realised gains, alongside a raised fully franked dividend and an extended share buy-back program.

Eildon Capital Group reported a net loss of $5.7 million for FY2025, weighed down by significant one-off impairments, while pivoting to focused real estate investments with a new $20.8 million joint venture in Queensland.

Pacific Current Group Limited reported a 3.3% decline in revenue and a 19% drop in underlying net profit after tax for FY25, alongside a major share buy-back and key portfolio restructurings.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Regis Healthcare delivered a robust FY25 performance with a 14.5% revenue increase and a dramatic turnaround to a $49 million net profit. The company is advancing growth through acquisitions and greenfield developments, positioning itself strongly ahead of upcoming sector reforms.

Adore Beauty Group reported a modest 1.6% revenue increase in FY25 to $198.8 million, while profit before tax fell 56% due to one-off acquisition and restructuring costs. The company’s integration of iKOU and retail expansion underpin a refreshed omni-channel growth strategy.